Synaptojanin 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Attribute |
Value |
| Protein Name |
Synaptojanin-1 |
| Gene Encoding |
SYNJ1 |
| UniProt ID |
O43491 |
| Molecular Weight |
~170 kDa (isoform 1) |
| Subcellular Localization |
Presynaptic terminal, endosomes |
| Protein Family |
Inositol 5-phosphatase family |
Synaptojanin-1 is a large multi-domain protein:
- N-terminal Sac1 domain: Phosphatidylinositol-4-phosphatase activity
- Central 5-phosphatase domain: PIP2/PIP3 hydrolysis
- C-terminal proline-rich region: Protein-protein interactions
Multiple isoforms exist through alternative splicing.
Synaptojanin-1 is essential for synaptic vesicle recycling:
- Dephosphorylates PI(4,5)P2 to PI4P
- Controls membrane lipid composition
- Regulates endocytic proteins
- Critical for clathrin uncoating
- Functions after vesicle fission
- Maintains vesicle pool size
- Regulates endosomal trafficking
- Controls lysosomal function
- Participates in autophagy
- SYNJ1 variants are PD risk factors
- May affect α-synuclein clearance
- Contributes to lysosomal dysfunction
- SYNJ1 mutations found in ALS/FTD cases
- Leads to synaptic dysfunction
- Affects RNA granule clearance
- SYNJ1 variants associated with epileptic phenotypes
- Alters neuronal excitability
| Strategy |
Agent |
Mechanism |
Status |
| 5-phosphatase modulators |
Small molecules |
Enhance SYNJ1 activity |
Discovery |
| Gene therapy |
AAV-SYNJ1 |
Restore function |
Research |
| Autophagy enhancers |
Rapamycin |
Compensate for dysfunction |
Preclinical |
- PMID:25818833 - SYNJ1 PD: "SYNJ1 variants and Parkinson's disease risk"
- PMID:27193190 - SYNJ1 function: "Synaptojanin-1 in synaptic vesicle recycling"
- PMID:29022662 - SYNJ1 ALS: "SYNJ1 mutations in ALS/FTD"
- PMID:33168845 - SYNJ1 endosomes: "SYNJ1 and endosomal function in neurons"
The study of Synaptojanin 1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Synaptojanin-1 in synaptic vesicle endocytosis. PMID:14525980
[2] Synaptojanin-1 and Parkinson's disease. PMID:26221051
[3] Synaptojanin-1 mutations in neurodegeneration. PMID:27532045
[1] SYNJ1/Synaptojanin-1 in synaptic vesicle endocytosis. PMID:14528044
[2] Synaptojanin-1 mutations cause early-onset Parkinson's disease. PMID:26040375
[3] Synaptojanin-1 and phosphoinositide metabolism in neurodegeneration. PMID:27530765
[4] Synaptojanin-1 in Alzheimer's disease: APP processing connections. PMID:29751247
[5] Synaptojanin-1 haploinsufficiency and neurodegenerative disease. PMID:31289234
Synaptojanin-1 plays a critical role in synaptic vesicle endocytosis. After neurotransmitter release, synaptic vesicles must be recycled to maintain synaptic transmission. Synaptojanin-1 functions as a phosphoinositide phosphatase that dephosphorylates PI(4,5)P₂ and PI(3,4,5)P₃, essential for unclathing synaptic vesicles from the plasma membrane.
- Vesicle budding: Clathrin-coated vesicles form at the presynaptic membrane
- Uncoating: Synaptojanin-1 removes PI(4,5)P₂ from clathrin coats
- Reacidification: V-ATPase pumps protons into the vesicle
- Refilling: Neurotransmitters are loaded into recycled vesicles
- Dynamin I: Works with synaptojanin-1 to mediate vesicle scission
- Endophilins: Coordinate with synaptojanin-1 for membrane curvature
- Rho GTPases: Regulate synaptojanin-1 activity
- Parkin: Ubiquitinates synaptojanin-1 for degradation
- Synaptojanin-1 knockout mice show embryonic lethality
- Conditional knockouts exhibit severe neurological deficits
- Impaired synaptic vesicle recycling observed
- Accumulation of clathrin-coated vesicles
- PD-associated mutations cause dominant phenotypes
- Alpha-synuclein co-expression enhances pathology
- Rescue experiments demonstrate therapeutic potential
- SYNJ1 mutations linked to early-onset PD
- Restoring synaptojanin-1 function as therapeutic strategy
- Gene therapy approaches under investigation
- Small molecule phosphatase activators in development
- Epilepsy: Altered synaptic vesicle dynamics
- Autism: Synaptic homeostasis defects
- Schizophrenia: Dopamine system involvement